These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Mihos CG; Salas MJ; Santana O Cardiol Rev; 2010; 18(6):298-304. PubMed ID: 20926939 [TBL] [Abstract][Full Text] [Related]
45. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. O'Connor PJ; Gray RJ; Maciosek MV; Fillbrandt KM; DeFor TA; Alexander CM; Weiss TW; Teutsch SM Prev Chronic Dis; 2005 Jul; 2(3):A05. PubMed ID: 15963307 [TBL] [Abstract][Full Text] [Related]
46. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328 [TBL] [Abstract][Full Text] [Related]
47. Inhibitors of HMG-CoA Reductase: Current and Future Prospects. Singh N; Tamariz J; Chamorro G; Medina-Franco JL Mini Rev Med Chem; 2009 Oct; 9(11):1272-83. PubMed ID: 19929805 [TBL] [Abstract][Full Text] [Related]
48. [The pleiotropic effects of statins]. Wolfovitz E Harefuah; 2005 Aug; 144(8):577-82, 597. PubMed ID: 16146158 [TBL] [Abstract][Full Text] [Related]
49. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Epstein M; Campese VM Am J Kidney Dis; 2005 Jan; 45(1):2-14. PubMed ID: 15696439 [TBL] [Abstract][Full Text] [Related]
50. Beyond the laboratory: clinical implications for statin pleiotropy. Halcox JP; Deanfield JE Circulation; 2004 Jun; 109(21 Suppl 1):II42-8. PubMed ID: 15173062 [TBL] [Abstract][Full Text] [Related]
51. Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels. Kumai T; Matsumoto N; Koitabashi Y; Takeba Y; Oonuma S; Sekine S; Tadokoro M; Kobayashi S Curr Med Chem Cardiovasc Hematol Agents; 2005 Jul; 3(3):195-201. PubMed ID: 15974884 [TBL] [Abstract][Full Text] [Related]
52. [Pleiotrophic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors)]. Igel M; Sudhop T; von Bergmann K Arzneimittelforschung; 2003; 53(8):545-53. PubMed ID: 13677244 [TBL] [Abstract][Full Text] [Related]
53. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Undas A; Celińska-Löwenhoff M; Kaczor M; Musial J Thromb Haemost; 2004 Jun; 91(6):1065-77. PubMed ID: 15175791 [TBL] [Abstract][Full Text] [Related]
54. Statins: the new aspirin? Veillard NR; Mach F Cell Mol Life Sci; 2002 Nov; 59(11):1771-86. PubMed ID: 12530513 [TBL] [Abstract][Full Text] [Related]
56. Pleiotropic effects of statins. Liao JK; Laufs U Annu Rev Pharmacol Toxicol; 2005; 45():89-118. PubMed ID: 15822172 [TBL] [Abstract][Full Text] [Related]
57. Pleiotropic effects of statins. - Basic research and clinical perspectives -. Zhou Q; Liao JK Circ J; 2010 May; 74(5):818-26. PubMed ID: 20424337 [TBL] [Abstract][Full Text] [Related]
58. HMG-Co A reductase inhibitors in the treatment of cardiovascular diseases: stabilization of coronary artery plaque. Morishita R; Tomita N; Ogihara T Curr Drug Targets; 2002 Oct; 3(5):379-85. PubMed ID: 12182229 [TBL] [Abstract][Full Text] [Related]
59. The Pleiotropic Effects of Statins in Endocrine Disorders. De La Cruz JA; Mihos CG; Horvath SA; Santana O Endocr Metab Immune Disord Drug Targets; 2019; 19(6):787-793. PubMed ID: 30924424 [TBL] [Abstract][Full Text] [Related]